Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Deals

Adicon Holdings and Guardant Health Partner on Genomic Profiling in China

Fineline Cube Jul 7, 2022

China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...

Company Deals

BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development

Fineline Cube Jul 7, 2022

China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...

Company Deals

PackGene and SineuGene Partner on ALS Gene Therapy Research

Fineline Cube Jul 7, 2022

China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...

Policy / Regulatory

China Establishes Leadership Group to Combat Drug-Related Crimes

Fineline Cube Jul 7, 2022

China’s State Council executive body released a notification regarding the establishment of a leadership group...

Company Deals Digital

Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push

Fineline Cube Jul 7, 2022

Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study

Fineline Cube Jul 7, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Company Drug

Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study

Fineline Cube Jul 6, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Drug

GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome

Fineline Cube Jul 6, 2022

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from...

Company Drug

Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study

Fineline Cube Jul 6, 2022

China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient...

Company Deals

ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion

Fineline Cube Jul 6, 2022

Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...

Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review

Fineline Cube Jul 6, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...

Company Deals

Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development

Fineline Cube Jul 6, 2022

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...

Drug

Ascletis Pharma Files IND Application for ASC10 with US FDA

Fineline Cube Jul 6, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...

Company Drug

MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jul 6, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment

Fineline Cube Jul 6, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...

Company Deals

Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion

Fineline Cube Jul 6, 2022

China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...

Company Drug

Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA

Fineline Cube Jul 6, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...

Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Posts pagination

1 … 599 600 601 … 612

Recent updates

  • BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform
  • Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery
  • Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform
  • Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials
  • GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.